




# Jornal de Pediatria

www.jpmed.com.br



## ORIGINAL ARTICLE

# Association between exanthematous diseases and early age at Type 1 diabetes diagnosis: a Brazilian cohort study

Q1 Lucas C.P. Lopes <sup>a,\*</sup>, Lenita Zajdenverg <sup>b</sup>, Rodrigo L.M. Martins <sup>a</sup>, Gabriel Araujo Medeiros <sup>a</sup>, Marina D. Louro <sup>a</sup>, João V.M. Lanzarin <sup>a</sup>, Carlos A. Negrato <sup>a</sup>

<sup>a</sup> Universidade de São Paulo, Faculdade de Medicina de Bauru, Bauru, SP, Brazil

<sup>b</sup> Universidade Federal do Rio de Janeiro, Hospital Universitário Clementino Fraga Filho, Departamento de Clínica Médica, Serviço de Nutrologia, Rio de Janeiro, RJ, Brazil

Received 13 July 2024; accepted 19 November 2024

Available online xxx

### KEYWORDS

Exanthematous disease;  
Type 1 diabetes mellitus;  
Cohort study

### Abstract

**Objective:** To assess the association between exanthematous diseases, and an early age at T1DM diagnosis in a cohort of Brazilian patients with T1DM.

**Methods:** This was a retrospective cohort study including 812 patients diagnosed with T1DM in Bauru, São Paulo, Brazil, between 1981 and 2023. Data regarding sociodemographic parameters such as age, sex, ethnicity, socioeconomic status, as well as the occurrence of a previous exanthematous diseases, such as chickenpox, measles, rubella, mumps and scarlet fever were collected. An adapted survival analysis was used to evaluate the impact of each variable on the age of T1DM diagnosis.

**Results:** Overall, 596 patients were evaluated. Their average age at T1DM diagnosis was  $12 \pm 7.69$  years. It was found that presenting rubella, measles, and mumps, as well as belonging to non-high socioeconomic class, were associated with 35%, 40%, 39%, and 34% lower age at T1DM diagnosis, respectively.

**Conclusions:** This study has found that rubella, measles, mumps, and belonging to non-high socioeconomic classes were significantly associated with earlier age at T1DM diagnosis in a cohort of Brazilian patients with T1DM. Future studies with other populations are warranted to confirm our findings.

© 2025 The Authors. Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de Pediatria. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

\* Corresponding author.

E-mail: [lucaspassoni@usp.br](mailto:lucaspassoni@usp.br) (L.C. Lopes).

<https://doi.org/10.1016/j.jpmed.2024.11.012>

0021-7557/© 2025 The Authors. Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de Pediatria. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Please cite this article in press as: L.C. Lopes, L. Zajdenverg, R.L. Martins et al., Association between exanthematous diseases and early age at Type 1 diabetes diagnosis: a Brazilian cohort study, *Jornal de Pediatria* (2025), <https://doi.org/10.1016/j.jpmed.2024.11.012>

## 1 Introduction

2 Insulin deficiency is the hallmark of type 1 diabetes mellitus  
3 (T1DM). This disease derives from an interplay between  
4 genetic and environmental factors.<sup>1</sup> The majority of cases,  
5 next to 90% of the total, is due to an autoimmune destruc-  
6 tion of pancreatic  $\beta$  cells, while about 10% are autoanti-  
7 body-negative.<sup>1</sup>

8 The incidence and prevalence of Type 1 Diabetes Mellitus  
9 (T1DM) are rising worldwide, including in Brazil.<sup>2</sup> Currently,  
10 nearly nine million people globally live with T1DM, and this  
11 number is expected to more than double by 2040.<sup>2</sup> Addition-  
12 ally, around four million people are believed to have undiag-  
13 nosed T1DM, with over 30,000 potentially dying within a  
14 year of disease onset.<sup>2,3</sup> Over half of T1DM cases occur in  
15 individuals under 20 years old, and one-fifth are in low-  
16 income countries. In Brazil, over 100,000 people have T1DM,  
17 with projections that this fig. will almost double in the com-  
18 ing decades.<sup>2,3</sup>

19 It has been shown in many studies that patients who have  
20 T1DM diagnosed at younger ages, tend to present more di-  
21 abetes-related complications and worse prognosis.<sup>4</sup> Conse-  
22 quently, understanding the underlying pathophysiological  
23 mechanisms involved in T1DM genesis is crucial for timely  
24 diagnosis and for altering its course, improving the quality  
25 of life and life expectancy of those affected individuals.<sup>4</sup>

26 A French study utilized a geographical approach to map  
27 the infectious environment of children before T1DM diagno-  
28 sis.<sup>5</sup> It was a retrospective study that evaluated 3548  
29 patients using data from the French Sentinel network.<sup>5</sup> It  
30 found associations between influenza-like infections and  
31 T1DM risk, while varicella infection appeared to be protec-  
32 tive.<sup>5</sup> In parallel, an Italian retrospective study evaluated  
33 the relationship between childhood infections such as mea-  
34 sles, mumps, and rubella and T1DM from 1996 to 2001.<sup>6</sup> It  
35 used a control group and found a significant association  
36 between T1DM incidence and mumps ( $P=0.034$ ) and rubella  
37 ( $P=0.014$ ) after excluding data from Sardinia.<sup>6</sup> Another Ital-  
38 ian study conducted between 1988 and 2000, with a case-  
39 control methodology noted that viral childhood diseases, as  
40 measles and Rubella, were directly correlated with T1DM  
41 (OR 4.29; 95% CI, 1.57–11.74).<sup>7</sup> Interestingly, an inverse cor-  
42 relation was observed with scarlet fever (OR 0.19; 95% CI,  
43 0.08–0.46), though the mechanism remains unclear.<sup>7</sup>

44 Therefore, the aim of this study was to assess the associa-  
45 tion between exanthematous diseases, with an early age at  
46 T1DM diagnosis in a cohort of Brazilian patients with T1DM.

## 47 Methods

### 48 Data source

49 This is a retrospective study that enrolled 812 patients diag-  
50 nosed with T1DM, who received medical care at an endocri-  
51 nology clinic in Bauru, São Paulo State, Brazil, from 1981 to  
52 2023.

53 The endocrinology clinic attended patients from private  
54 and public systems. The private patients were those who  
55 searched for the clinic and paid for the services. The public  
56 patients were those who were referral from the Bauru's Dia-  
57 betic Association, a non-profit organization focused on the

reception, screening, diagnosis, and monitoring of patients  
with diabetes. Thus, a broad population sample was encom-  
passed. This clinic is managed by a single endocrinologist  
with extensive clinical experience in the area and with sev-  
eral studies already carried out and published on the sub-  
ject.

Were included all patients who were treated at the afore-  
mentioned clinic and who had a previous diagnosis of T1DM  
or obtained it after an evaluation with the previously men-  
tioned endocrinologist between 1981 and 2023. There was  
no age limit on patient's evaluation.

All evaluated data are provided from the self-report of  
the patients and/or their parents. The researchers accessed  
the data through their evaluation of medical records in  
which the data were handwritten.

### Data categorization

The data were categorized into two different categories.  
Sociodemographic data collected included age at T1DM diag-  
nosis, sex, ethnicity, and socioeconomic status. Clinical data  
primarily focused on the history of exanthematous diseases  
of viral or bacterial etiology, such as chickenpox, measles,  
rubella, mumps, and scarlet fever.

T1DM diagnoses were made by physicians based in clinical  
protocols and guidelines issued by the Brazilian Ministry of  
Health, which have been periodically revised over the years.  
The diagnosis encompassed classical clinical signs and symp-  
toms, that is, polyuria, polyphagia, polydipsia, weight loss,  
need for insulin to control glycemia and the occurrence of a  
previous diabetic ketoacidosis episode. Although glycated  
hemoglobin levels and autoantibodies may also serve as cri-  
teria for T1DM diagnosis, they were not used because they  
were not available to a wide range of evaluated patients.

Ethnicity was classified as White, Black, Brown, Yellow, or  
Indigenous based on self-reported data in according to the  
classification proposed by the Instituto Brasileiro de Geogra-  
fia e Estatística (IBGE).<sup>8</sup> For statistical purposes, Blacks,  
Browns and Yellow were grouped into "Non-whites".

Socioeconomic classification was based on the average  
monthly income of the families evaluated. In this case,  
patients were categorized into class A (income greater than  
20 minimum wages), B (income between 10 and 20 minimum  
wages), C (income between 4 and 10 minimum wages), D  
(income between 2 and 4 minimum wages) and E (income  
less than 2 minimum wages). This classification was based on  
the self reported income of the evaluated patients and in  
accordance with the classification proposed by the  
Associação Brasileira de Empresas de Pesquisa.<sup>9</sup> The mini-  
mum wage corresponding to each family's classification cor-  
responds to the minimum wage of the year in which the  
patients were evaluated, in order to make their socioeco-  
nomic condition more realistic to the reality presented at  
each time. For statistical purposes, classes A and B were  
grouped into "High-classes" and classes C to E were grouped  
into "Non-high classes".

The history of previous exanthematous disease was  
obtained from reports made by the patients and/or their  
parents. In this case, they were asked about the occurrence  
of typical symptoms of each condition investigated, the  
presence/absence of a positive serology, complementary  
tests performed. A structured protocol with literature

118 references was not used. However, the assessment of the  
119 occurrence of exanthematous diseases occurred in a system-  
120 atic and standardized manner, always by the same physician  
121 who deal with all patients. Furthermore, the history was  
122 reassessed in other consultations with the patient, seeking  
123 to confirm the occurrence of the condition under investiga-  
124 tion. We did not have access to vaccination status of the  
125 evaluated individuals

## 126 Data analysis

127 For statistical analysis, R 4.4.0 alpha Software® was used.  
128 Initially, a descriptive analysis was performed and subse-  
129 quently, a modified survival analysis was carried out to eval-  
130 uate the impact of each variable on the age of T1DM  
131 diagnosis (the event of interest). Hazard ratios (HR) were  
132 determined: values between 0 and 1 indicated a lower aver-  
133 age age at T1DM diagnosis, 1 signified no change, and values  
134 above 1 indicated an increased average age at diagnosis. A  
135 p-value < 0.05 was considered statistically significant.

## 136 Ethical considerations

137 This study received approval from the Research Ethics Com-  
138 mittee of the Bauru School of Dentistry, University of São  
139 Paulo, under protocol number: 4.872.670.

## 140 Results

141 Out of 812 patients initially evaluated, only 596 patients  
142 formed the final sample. Overall, 27 individuals did not have  
143 information regarding an infection by chickenpox; 32 by  
144 measles; 26 by rubella; 45 by mumps; 18 by scarlet fever.  
145 Moreover, 29 patients chose not to declare their socioeco-  
146 nomic class.

The analyzed sample was formed by 310 (51.92%) women 147  
and 286 (48.08%) men; 487 (81.75%) Whites, 38 (6.35%) Blacks 148  
68 Browns (11.40%) 3 (0.50%) Yellows, totalizing 487 (81.75%) 149  
Whites and 109 (18.25%) non-Whites; 255 (42.71%) from high 150  
socioeconomic class, 176 (29.53%) from medium class, 120 151  
(20.16%) from low class, and 45 (7.60%) from very low class, 152  
totalizing 255 (42.71%) from high socioeconomic class and 341 153  
(57.29%) from non-high socioeconomic class. The characteris- 154  
tics of the sample studied are summarized in Table 1. 155

The average age at T1DM diagnosis was  $12 \pm 7.69$  years. 156  
Figure 1 shows the age of patients distribution. Those indi- 157  
viduals that presented a previous diagnosis of rubeola (HR 158  
0.65 CI, 0.51–0.84  $p < 0.01$  – Fig. 2), measles (HR: 0.60 CI, 159  
0.48–0.74  $p < 0.01$  – Fig. 3), as well as mumps (HR: 0.61 CI, 160  
0.50–0.73  $p < 0.01$  – Fig. 4), and those who were from non- 161  
high socioeconomic class (0.66 CI, 0.56–0.78  $p < 0.01$  – Fig. 162  
5) tended to present a 35%, 40%, 39% and 34% lower age at 163  
T1DM diagnosis than those individuals that did not present 164  
these diseases, and were from high socioeconomic class, 165  
respectively. Figs. 2–5 are supplementary material. When 166  
compared Whites with Blacks, Browns, Yellows and Indige- 167  
nous, no statistically significant differences were observed. 168  
When compared A socioeconomic class with B, C, D and E, 169  
no significant statistical differences were observed. The 170  
other evaluated characteristics did not show statistical sig- 171  
nificance in the analysis performed (Table 2). 172


## 173 Discussion

### 174 Summary of the results

175 Of 812 patients initially enrolled, only 596 were included in 176  
the final sample. It was found that, in this group, the aver- 177  
age age at T1DM diagnosis was  $12 \pm 7.69$  years. The evalu- 178  
ated variables were sex, ethnicity, socioeconomic class, and

Table 1 Socioeconomic and demographic data of the studied patients.

Group	Evaluated patients	Average age at T1DM diagnosis	Standard deviation	Range	Hazard ratio	95% confidence interval	p-value
Total sample	596	12.00	7.69	1–44	–	–	–
Whites	487	12.20	7.99	1–44	1.19	0.96–1.47	0.09
Non-Whites	109	11.10	6.13	1–29	–	–	–
Whites	487	12.20	7.99	1–44	–	–	–
Blacks	41	11.70	7.55	2–27	0.95	0.87–1.13	0.23
Browns	58	10.80	7.13	1–29	0.87	0.75–1.04	0.15
Yellows	6	11.40	7.89	2–25	0.93	0.87–1.15	0.64
Indigenous	4	10.50	7.27	1–22	0.79	0.59–1.06	0.10
Men	286	11.70	7.88	1–37	0.94	0.80–1.11	0.49
Women	310	12.30	7.49	1–44	–	–	–
High socioeconomic class	255	13.20	8.56	1–44	–	–	–
Non-high socioeconomic class	341	10.30	5.97	1–37	0.66	0.56–0.78	$p < 0.01$
A	45	12.80	7.92	1–28	–	–	–
B	210	12.70	7.56	1–44	0.98	0.85–1.11	0.21
C	150	10.20	6.32	1–37	0.65	0.42–1.06	0.16
D	130	10.10	5.80	1–33	0.62	0.57–1.04	0.19
E	61	11.30	5.15	1–29	0.73	0.59–1.02	0.08



**Figure 1** Age at type 1 diabetes mellitus diagnosis distribution. X axis, age (years); Y axis, amount.

179 the presence or absence of a previous exanthematous disease (rubella, chickenpox, measles, mumps, and scarlet fever). Those individuals that presented rubella, measles, 182 mumps and were from non-high socioeconomic class tended to present a 35%, 40%, 39%, and 34% lower age at T1DM diagnosis than those individuals who did not present these diseases, and were from high socioeconomic class, 186 respectively.

### 187 Viral factors

188 Our findings suggest an association between rubella, mumps, 189 and measles infections and an earlier age of T1DM diagnosis, 190 as these diseases predominantly occur in childhood. An 191 observational study conducted with Finnish children found 192 that mumps infection could act as a trigger for the early 193 development of DM1 which is in accordance with the results 194 from one of the previously cited Italian articles.<sup>6,10</sup> In parallel, 195 a literature review discussed that chickenpox infections 196 could be this triggering actor, in contrast with the previously 197 mentioned French study.<sup>5,11</sup> Another study found higher 198 rates of T1DM diagnosis in regions of Italy with significant 199 incidences of mumps, measles, and rubella. But it did not 200 discuss the individual impact of each one of these diseases

201 under T1DM diagnosis age, unlike the other two Italian studies 202 cited above that observed an significant relationship 203 rubella infections and early cases of T1DM.<sup>5,6,12</sup>

204 Several hypothesis have been proposed to explain the 205 relationship between viral infections and the age of T1DM 206 diagnosis.<sup>5,13-15</sup> It has been suggested that certain viruses 207 may alter the expression of specific genes within the HLA 208 class by inserting their genetic material into host 209 cells.<sup>5,13-15</sup> By this mechanisms, they are able to modulate 210 cell genetic expression, promoting the synthesis of proteins 211 essential for viral replication.<sup>5,13-15</sup> Consequently, this process 212 may inhibit the production of key human proteins, such 213 as insulin and its receptors, ultimately contributing to the 214 onset of T1DM.<sup>5,13-15</sup>

215 Additionally, viruses may provoke an erratic immune 216 response, wherein antibodies mistakenly target the host's 217 own proteins, leading to the autoimmune destruction of specific 218 cells, such as pancreatic beta cells.<sup>5,13-15</sup> This destruction 219 results in insulin deficiency, culminating in T1DM.<sup>5,13-15</sup>

220 It has also been hypothesized that certain viruses can 221 induce a chronic inflammatory state, which disrupts immune 222 system modulation.<sup>5,13-15</sup> This impaired immune response 223 may prevent the effective clearance of viruses, favoring processes 224 like apoptosis of pancreatic beta cells and fibrosis of the 225 pancreas.<sup>5,13-15</sup>

226 Children, with their developing immune systems, are particularly 227 susceptible to viral infections.<sup>5,13-15</sup> This increased 228 vulnerability could lead to a higher number of infected cells, 229 alterations in protein synthesis, and a greater tendency 230 towards chronic and erratic immune responses.<sup>5,13-15</sup> Consequently, 231 T1DM may manifest at an earlier age during 232 childhood.<sup>5,13-15</sup>

233 Interestingly, some studies suggest that certain viral 234 infections might confer protection against T1DM.<sup>16,17</sup> This 235 protection could be mediated by the immune response to 236 viral infections, which involves pro-inflammatory agents 237 such as Th1 lymphocytes and cytokines like TNF- $\alpha$  and interleukins 238 12 and 17.<sup>16,17</sup> Simultaneously, immunomodulatory 239 agents, including T helper cells, B lymphocytes, and interleukins 240 4 and 13, may counterbalance and regulate this immune activity, 241 preventing uncontrolled immune attacks that lead to T1DM.<sup>16,17</sup> 242 Furthermore, upon reinfection with the same or a similar virus, 243 the immune system responds more rapidly and effectively, 244 preventing the onset of autoimmune mechanisms and delaying or 245 avoiding T1DM onset.<sup>16,17</sup> This may explain why we did not observe 246

**Table 2** Exanthematous disease infections in the studied patients.

Group	Evaluated patients	Average age at T1DM diagnosis	Standard deviation	Range	Hazard ratio	95% confidence interval of 95%	p-value
Previous chickenpox	154	10.90	7	1-43	0.85	0.72-1.01	$p = 0.06$
No previous chickenpox	442	15	8.72	1-44	-	-	-
Previous measles	113	11.20	7.06	1-43	0.60	0.48-0.74	$p < 0.01$
No previous measles	483	15.50	9.50	1-44	-	-	-
Previous rubella	72	11.50	7.53	1-44	0.65	0.58-0.84	$p < 0.01$
No previous rubella	524	15.60	7.99	1-34	-	-	-
Previous mumps	382	11.10	7.61	1-43	0.61	0.50-0.73	$p < 0.01$
No previous mumps	214	12.50	7.64	1-44	-	-	-
Previous scarlet fever	572	11.90	7.63	1-44	0.77	0.51-1.16	$p = 0.21$

247 association between a history of chickenpox and earlier  
248 T1DM diagnosis and the disagreement between the studies  
249 cited above.

250 Studies released in the early 2020's decade have also  
251 reported an increase in T1DM incidence following Sars-Cov-2  
252 infection.<sup>18</sup> A systematic review and meta-analysis pub-  
253 lished in late 2022 noted that patients with a history of  
254 COVID-19 had up to a 66% higher risk of developing T1DM  
255 (Risk Ratio: 1.66, Confidence interval 95: 1.38–2.00).<sup>18</sup> The  
256 spike protein of this virus may provoke a systemic inflamma-  
257 tory response that affects the pancreas, potentially trigger-  
258 ing T1DM.<sup>18–20</sup> A Spanish study noted that patients  
259 diagnosed with COVID-19 tended to develop T1DM at a later  
260 age possibly due to delays in recognizing T1DM symptoms or  
261 seeking medical care during the pandemic.<sup>19</sup> Conversely,  
262 the SWEET Study Group observed an increase in T1DM diag-  
263 noses across various age groups but did not associate this  
264 rise with a specific age group.<sup>20</sup> This may be explained by  
265 other factors, such as psychosocial stress or co-circulation of  
266 other viral agents, which also act as T1DM triggers and were  
267 influenced by the COVID-19 pandemic across different age  
268 groups.<sup>20</sup>

## 269 Bacterial factors

270 Regarding bacterial infections, some studies suggest that  
271 certain bacteria might influence the complex interplay  
272 underlying T1DM pathogenesis.<sup>21</sup> It has been proposed that  
273 bacterial agents can mimic or alter the expression of human  
274 antigens, such as HLA genes, thereby triggering or protect-  
275 ing against uncontrolled autoimmune responses that lead to  
276 cellular destruction and T1DM.<sup>21</sup>

277 We did not find a statistically significant association  
278 between the history of scarlet fever and early T1DM diagno-  
279 sis. Interestingly, an Italian case-control study conduct  
280 between 1988 and 2000, and a Belarus retrospective cohort  
281 conducted between 1980 and 2001 reported that individuals  
282 with a history of scarlet fever tended to be diagnosed with  
283 T1DM at older ages.<sup>8,22</sup> This discrepancy could be explained  
284 by individual genetic and epigenetic factors that modulate  
285 erratic immune responses to infections caused by group A  
286 beta-hemolytic *Streptococcus*, preventing the development  
287 of T1DM in some individuals.<sup>8,22</sup>

## 288 Vaccines

289 Some studies suggest that immune activation induced by  
290 vaccination could potentially precipitate autoimmune reac-  
291 tions, acting as a catalyst for T1DM development.<sup>23,24</sup> Vac-  
292 cines for rubella and influenza, in particular, have been  
293 associated with an increased risk of T1DM due to their immu-  
294 nogenic properties.<sup>23,24</sup> However, these findings remain  
295 inconclusive due to variations in sample sizes, follow-up  
296 durations, and diagnostic criteria across studies.<sup>23–25</sup>

297 In contrast, other studies have argued that vaccines may  
298 protect against T1DM by preventing infections that would  
299 trigger excessive immune responses.<sup>4</sup> Under this perspec-  
300 tive, some studies propose that vaccines might reduce the  
301 burden on the immune system, thereby preventing the auto-  
302 immune processes that lead to T1DM.<sup>26,27</sup> A Canadian case-  
303 control study developed between the 1970s and 1980s found  
304 that children who received the *Bacillus Calmette-Guérin*

(BCG) vaccine had a lower incidence of early-onset T1DM.<sup>26</sup> 305  
306 Additionally, a narrative review published in 2021 suggested  
307 that the idea of vaccines as T1DM triggers has been largely  
308 debunked, although ongoing discussions persist due to the  
309 incomplete understanding of certain vaccines' immunogenic  
310 mechanisms.<sup>27</sup>

## 311 Individual factors

312 We found an association between lower socioeconomic sta-  
313 tus and earlier age of T1DM diagnosis. The literature, how-  
314 ever, does not present a clear consensus linking a specific  
315 socioeconomic stratum to T1DM onset.<sup>28,29</sup>

316 A study conducted with data from Brazil did not observe a  
317 significant difference between the socioeconomic status of  
318 the individual and the prevalence and age at diagnosis of  
319 T1DM.<sup>28</sup> In parallel, a cross-sectional multicenter North-  
320 American study suggested that patients from lower socio-  
321 economic strata had worse glycemic control rates, which  
322 could impact under T1DM development.<sup>29</sup>

323 The referenced studies indicate that disparities in access  
324 to health technologies and services across different socio-  
325 economic groups can play a significant role in the develop-  
326 ment and management of T1DM.<sup>28,29</sup> Variations in access to  
327 early diagnostics, routine health screenings, and advanced  
328 care may contribute to delayed diagnosis or suboptimal dis-  
329 ease management, potentially leading to more rapid pro-  
330 gression of the disease in lower-income populations.<sup>28,29</sup>  
331 Additionally, these disparities can influence the onset of  
332 T1DM, particularly where preventive care and timely inter-  
333 vention are less accessible.<sup>28,29</sup>

334 A review conducted by North-American and British  
335 researches highlight the role of genetic risk scores across  
336 diverse ancestries in T1DM development, emphasizing that  
337 ancestry-related differences may influence the disease's  
338 onset.<sup>30</sup> Similarly, a study conducted using a population-  
339 based registry from Italy discuss that sex and ethnicity may  
340 impact under T1DM development by an interaction between  
341 genes and epigenetic factors.<sup>31</sup> Both studies discuss that  
342 there is no clear relationship between a specific sex and eth-  
343 nicity and the risk of developing T1DM.<sup>30,31</sup> This occurs  
344 because the genetic load of each group and the environmen-  
345 tal factors that act in the modulation of these genes and  
346 may act as triggers for T1DM vary between each location on  
347 the globe.<sup>30,31</sup> Furthermore, it should be mentioned that  
348 these studies did not focus on the potential relationship  
349 between early T1DM onset and childhood exanthematous  
350 diseases, which remains an area requiring further  
351 investigation.<sup>30,31</sup>

## 352 Epidemiology of the evaluated diseases

353 The incidence and prevalence of the diseases evaluated in  
354 this research have been decreasing over the years.<sup>32,33</sup> In  
355 fact, this derives from the Brazilian national immunization  
356 program that provides free and widely accessible vaccines  
357 to the population.<sup>32</sup> Furthermore, advances in diagnosis and  
358 treatment also contribute to better control of these condi-  
359 tions.<sup>33</sup> However, in recent years, a resurgence of these con-  
360 ditions has been observed. In this sense, some studies  
361 conducted in Brazil observed that the prevalence of protec-  
362 tive antibodies against certain diseases such as Measles and

363 Rubella are absent in up to 20% of the target audience for  
 364 immunizations.<sup>32,33</sup> This is possible explained by a decrease  
 365 in vaccination coverage rates in children.<sup>32,33</sup>  
 366 To the best of our knowledge, there is no precise epi-  
 367 demiological study indicating the incidence and preva-  
 368 lence of the exanthematous diseases evaluated among  
 369 the general population. However, it is suggested that  
 370 cases of these conditions occur predominantly in chil-  
 371 dren, with some cases in adults being associated with  
 372 wild viral and bacterial strains that infect previously non-  
 373 immunized individuals.<sup>32,33</sup>

### 374 Limitations and strengths

375 One of the main limitations of this study is the potential for  
 376 diagnostic and memory bias due to reliance on self-reported  
 377 data, particularly in the case of exanthematous diseases.  
 378 Furthermore, the lack of detailed information on patients'  
 379 vaccination status represented a significant another limita-  
 380 tion of the study. Finally, a longitudinal cohort design would  
 381 provide an evidence to assess the potential association  
 382 between infectious diseases and T1DM, following children  
 383 over time to observe whether prior infectious diseases dif-  
 384 ferentiate those who later develop T1DM from those who do  
 385 not.

386 Several measures were taken in this study to mitigate  
 387 potential limitation. First, all diagnoses and historical data  
 388 regarding exanthematous diseases were systematically eval-  
 389 uated by the same experienced endocrinologist, ensuring  
 390 consistency in patient assessments over time. This standard-  
 391 ized approach, combined with the regular reassessment of  
 392 medical histories in subsequent consultations, helped con-  
 393 firm the accuracy of the reported conditions. Additionally,  
 394 the inclusion of a wide population sample, drawn from both  
 395 private and public healthcare systems, enhances the gener-  
 396 alizability of the findings. By covering such a long time-  
 397 frame, involving multiple points of reassessment, and  
 398 evaluating a wide range of clinical and demographic charac-  
 399 teristics this study addresses some limitations inherent in  
 400 retrospective designs and provides a robust basis for future  
 401 prospective research on the relationship between infectious  
 402 diseases and T1DM.

403 One of the key strengths of this study is its extensive lon-  
 404 gitudinal coverage, spanning over four decades  
 405 (1981–2023), which allowed for the inclusion of a diverse  
 406 and broad population sample from both public and private  
 407 healthcare systems. This comprehensive timeframe enables  
 408 a thorough exploration of the natural history T1DM across  
 409 different socioeconomic contexts and healthcare access lev-  
 410 els. Additionally, the standardized clinical approach  
 411 employed by a single, highly experienced endocrinologist  
 412 throughout the study period minimizes inter-observer vari-  
 413 ability, ensuring consistency in diagnoses and patient man-  
 414 agement. The use of real-world clinical data, obtained from  
 415 medical records, also enhances the study's external validity,  
 416 making the findings more applicable to general clinical prac-  
 417 tice. This study thus contributes valuable insights into the  
 418 potential associations between exanthematous diseases and  
 419 T1DM, while also providing a foundation for future prospec-  
 420 tive research.

## Conclusion

This study has found that rubella, measles, mumps, and  
 belonging to non-high socioeconomic classes were signifi-  
 cantly associated with earlier age at T1DM diagnosis in a  
 cohort of Brazilian patients with T1DM. Future studies with  
 other populations are warranted to confirm our findings.

## Authors' contributions

Lucas Casagrande Passoni Lopes participated in the concep-  
 tion and design of the study; data acquisition, data analysis  
 and interpretation, final approval of the version to be sub-  
 mitted; Rodrigo Lima de Meo Martins, Marina Donda Louro,  
 Gabriel Araujo Medeiros, João Vitor Mota Lanzarin partici-  
 pated in data acquisition, analysis and interpretation of  
 data and final approval of the version to be submitted;  
 Lenita Zajdenverg and Carlos Antonio Negrato participated  
 in drafting the article and revising it critically for important  
 intellectual content.

## Conflicts of interest

The authors declare no conflicts of interest.

## Acknowledgments

To reviewers and editor from Journal de Pediatria by the sug-  
 gestions and corrections that improved our manuscript qual-  
 ity.

To the Universidade de São Paulo for the encouragement  
 and support.

## Supplementary materials

Supplementary material associated with this article can  
 be found in the online version at [doi:10.1016/j.jpmed.2024.11.012](https://doi.org/10.1016/j.jpmed.2024.11.012).

## Editor

C. de A.D Alves

## References

1. Negrato CA, Lauris JR, Saggiaro IB, Corradini MC, Borges PR, Crês MC, et al. Increasing incidence of type 1 diabetes between 1986 and 2015 in Bauru, Brazil. *Diabet Res Clin Pract.* 2017;127:198–204.
2. Gregory GA, Robinson TI, Linklater SE, Wang F, Colagiuri S, de Beaufort C, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. *Lancet Diabet Endocrinol.* 2022;10:741–60.
3. International Diabetes Federation. *IDF Diabetes Atlas. 10th edn.* Brussels, Belgium: International Diabetes Federation; 2021. Available from: <https://diabetesatlas.org/data/en/country/27/br.html>. Accessed: 05 Dec 2024.

- 465 4. Pierce JS, Kozikowski C, Lee JM, Wysocki T. Type 1 diabetes in  
466 very young children: a model of parent and child influences on  
467 management and outcomes. *Pediatr Diabetes*. 2017;18:17–25.
- 468 5. Bougnères P, Le Fur S, group Isis-Diab collaborative, Valtat S,  
469 Kamatani Y, Lathrop M, et al. Using spatio-temporal surveil-  
470 lance data to test the infectious environment of children before  
471 type 1 diabetes diagnosis. *PLoS ONE*. 2017;12:e0170658.
- 472 6. Ramondetti F, Sacco S, Comelli M, Bruno G, Falorni A, Iannilli A,  
473 et al. Type 1 diabetes and measles, mumps and rubella child-  
474 hood infections within the Italian insulin-dependent diabetes  
475 registry. *Diabet Med*. 2012;29:761–6.
- 476 7. Tenconi MT, Devoti G, Comelli M, Pinon M, Capocchiano A, Cal-  
477 caterra V, et al. Major childhood infectious diseases and other  
478 determinants associated with type 1 diabetes: a case-control  
479 study. *Acta Diabetol*. 2007;44:14–9.
- 480 8. Instituto Brasileiro de Geografia e Estatística (IBGE). Classi-  
481 ficação Socioeconômica Brasil: Critérios De Estratificação. Rio  
482 de Janeiro: IBGE; 2010.
- 483 9. Associação Brasileira de Empresas de Pesquisa (ABEP). Critério  
484 Brasil de Classificação Econômica Available from: [http://www.  
485 abep.org/criterio-brasil](http://www.abep.org/criterio-brasil); 2019. Accessed: 05 Dec 2024.
- 486 10. Linder M. Chicken pox and childhood diabetes. *Diabetes Care*.  
487 1994;17:940–1.
- 488 11. Hyöty H, Hiltunen M, Reunanen A, Leinikki P, Vesikari T, Louna-  
489 maa R, et al. Decline of mumps antibodies in type 1 (insulin-  
490 dependent) diabetic children and a plateau in the rising inci-  
491 dence of type 1 diabetes after introduction of the mumps-meas-  
492 les-rubella vaccine in Finland. *Childhood diabetes in Finland  
493 Study Group. Diabetologia*. 1993;36:1303–8.
- 494 12. Bazzano S, Devoti G, D’Annunzio G, Capocchiano A, Maccarini L,  
495 Tenconi MT, et al. Variazioni di incidenza (1988–2000) del dia-  
496 bete mellito tipo 1 (T1DM) nella provincia di Pavia. *GIDM*.  
497 2003;23:119–25.
- 498 13. Roep BO. A viral link for type 1 diabetes. *Nat Med*. 2019;  
499 25:1816–8.
- 500 14. Rajsfus BF, Mohana-Borges R, Allonso D. Diabetogenic viruses:  
501 linking viruses to diabetes mellitus. *Heliyon*. 2023;9:e15021.
- 502 15. Filippi CM, von Herrath MG. Viral trigger for type 1 diabetes:  
503 pros and cons. *Diabetes*. 2008;57:2863–71.
- 504 16. Reschke F, Lanzinger S, Herczeg V, Prahalad P, Schiaffini R, Mul D,  
505 et al. The COVID-19 pandemic affects seasonality, with increas-  
506 ing cases of new-onset type 1 diabetes in children, from the  
507 worldwide SWEET registry. *Diabetes Care*. 2022;45:2594–601.
- 508 17. Cinek O, Kramna L, Lin J, Oikarinen S, Kolarova K, Ilonen J,  
509 et al. Imbalance of bacteriome profiles within the Finnish Dia-  
510 betes Prediction and Prevention study: parallel use of 16S profil-  
511 ing and virome sequencing in stool samples from children with  
512 islet autoimmunity and matched controls. *Pediatr Diabetes*.  
513 2017;18:588–98.
- 514 18. Ssentongo P, Zhang Y, Witmer L, Chinchilli VM, Ba DM. Associa-  
515 tion of COVID-19 with diabetes: a systematic review and meta-  
516 analysis. *Sci Rep*. 2022;12:20191.
- 517 19. Hernández Herrero M, Terradas Mercader P, Latorre Martínez E,  
518 Feliu Rovira A, Rodríguez Zaragoza N, Parada Ricart E. New  
519 diagnoses of type 1 diabetes mellitus in children during the  
520 COVID-19 pandemic regional multicenter study in Spain. *Endo-  
521 crinol Diabetes Nutr (Engl Ed)*. 2022;69:709–14.
- 522 20. Reschke F, Lanzinger S, Herczeg V, Prahalad P, Schiaffini R, Mul  
523 D, et al. The COVID-19 pandemic affects seasonality, with  
524 increasing cases of new-onset type 1 diabetes in children, from  
525 the worldwide SWEET registry. *Diabetes Care*. 2022;  
526 45:2594–601.
- 527 21. Dorman JS, Bunker CH. HLA-DQ locus of the human leukocyte  
528 antigen complex and type 1 diabetes mellitus: a HuGE review.  
529 *Epidemiol Rev*. 2000;22:218–27.
- 530 22. Uloha AI, Lialikau SA. Zależność między cukrzyca typu 1 a  
531 ostrymi zakażeniami u dzieci [The relationship between insulin-  
532 dependent diabetes mellitus and acute infections in children].  
533 *Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw*.  
534 2003;9:73–6.
- 535 23. Burgess MA, Forrest JM. Congenital rubella and diabetes melli-  
536 tus. *Diabetologia*. 2009;52:369–70. author reply 373.
- 537 24. Goto A, Takahashi Y, Kishimoto M, Nakajima Y, Nakanishi K,  
538 Kajio H, et al. A case of fulminant type 1 diabetes associated  
539 with significant elevation of mumps titers. *Endocr J*. 2008;  
540 55:561–4.
- 541 25. Morgan E, Halliday SR, Campbell GR, Cardwell CR, Patterson  
542 CC. Vaccinations and childhood type 1 diabetes mellitus: a  
543 meta-analysis of observational studies. *Diabetologia*. 2016;  
544 59:237–43.
- 545 26. Parent ME, Siemiatycki J, Menzies R, Fritschi L, Colle E. Bacille  
546 Calmette-Guérin vaccination and incidence of IDDM in Mon-  
547 treal, Canada. *Diabetes Care*. 1997;20:767–72.
- 548 27. Esposito S, Mariotti Zani E, Torelli L, Scavone S, Petraroli M,  
549 Patianna V, et al. Childhood vaccinations and type 1 diabetes.  
550 *Front Immunol*. 2021;12:667889.
- 551 28. Negrato CA, Martins RL, Louro MD, Medeiros GA, Lanzarin JV,  
552 Zajdenverg L, et al. Association between perinatal and obstet-  
553 ric factors and early age at diagnosis of type 1 diabetes melli-  
554 tus: a cohort study. *J Pediatr Endocrinol Metab*. 2024;  
555 37:673–9.
- 556 29. Agarwal S, Kanapka LG, Raymond JK, Walker A, Gerard-Gonza-  
557 lez A, Kruger D, et al. Racial-ethnic inequity in young adults  
558 with type 1 diabetes. *J Clin Endocrinol Metab*. 2020;105:  
559 e2960–9.
- 560 30. Redondo MJ, Gignoux CR, Dabelea D, Hagopian WA, Onengut-  
561 Gumuscu S, Oram RA, et al. Type 1 diabetes in diverse ances-  
562 tries and the use of genetic risk scores. *Lancet Diabet Endocri-  
563 nol*. 2022;10:597–608.
- 564 31. Altobelli E, Petrocelli R, Verrotti A, Chiarelli F, Marziliano C.  
565 Genetic and environmental factors affect the onset of type 1  
566 diabetes mellitus. *Pediatr Diabet*. 2016;17:559–66.
- 567 32. Estofotele CF, Milhim BH, França CC, Silva GC, Augusto MT, Ter-  
568 zian AC, et al. Prevalence of Measles antibodies in São José do  
569 Rio Preto, São Paulo, Brazil: a serological survey model. *Sci  
570 Rep*. 2020;10:5179.
- 571 33. Segatto C, Samad S, Mengue SS, Rodrigues G, Flannery B,  
572 Toscano CM. Historical analysis of birth cohorts not vaccinated  
573 against rubella prior to national rubella vaccination campaign.  
574 *Brazil J Infect Dis*. 2011;204(Suppl 2):S608–15.